The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jun. 17, 2025

Filed:

Feb. 02, 2022
Applicants:

Genentech, Inc., South San Francisco, CA (US);

Foundation Medicine, Inc., Cambridge, MA (US);

Inventors:

Richard Bourgon, South San Francisco, CA (US);

David Fabrizio, Cambridge, MA (US);

Gregg Fine, South San Francisco, CA (US);

Garrett M. Frampton, Cambridge, MA (US);

Priti Hegde, South San Francisco, CA (US);

Sanjeev Mariathasan, South San Francisco, CA (US);

Philip J. Stephens, Cambridge, MA (US);

James Xin Sun, Cambridge, MA (US);

Roman Yelensky, Newton, MA (US);

Assignees:

Genentech, Inc., South San Francisco, CA (US);

Foundation Medicine, Inc., Cambridge, MA (US);

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
C07K 16/28 (2006.01); A61K 39/395 (2006.01); A61P 35/00 (2006.01); G16H 50/30 (2018.01); A61K 39/00 (2006.01); G16H 20/10 (2018.01);
U.S. Cl.
CPC ...
C07K 16/2896 (2013.01); A61K 39/3955 (2013.01); C07K 16/2818 (2013.01); G16H 50/30 (2018.01); A61K 2039/505 (2013.01); A61K 2039/577 (2013.01); A61P 35/00 (2018.01); C07K 2317/24 (2013.01); C07K 2317/76 (2013.01); G16H 20/10 (2018.01);
Abstract

The present invention provides therapeutic and diagnostic methods and compositions for cancer, for example, bladder cancer. The invention provides methods of treating bladder cancer, methods of determining whether a patient suffering from bladder cancer is likely to respond to treatment comprising a PD-L1 axis binding antagonist, methods of predicting responsiveness of a patient suffering from bladder cancer to treatment comprising a PD-L1 axis binding antagonist, and methods of selecting a therapy for a patient suffering from bladder cancer, based on somatic mutation levels of genes of the invention (e.g., somatic mutation levels in a tumor sample obtained from the patient).


Find Patent Forward Citations

Loading…